Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136–52.

Article  PubMed  Google Scholar 

Passweg JR, Baldomero H, Basak GW, Chabannon C, Corbacioglu S, Duarte R, et al. The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies. Bone Marrow Transplant. 2019;54(10):1575–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood. 2008;112(12):4371–83.

Article  CAS  PubMed  Google Scholar 

D’Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, et al. Current use of and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant. 2020;26(8):e177–82.

Article  PubMed  PubMed Central  Google Scholar 

Horowitz M, Schreiber H, Elder A, Heidenreich O, Vormoor J, Toffalori C, et al. Epidemiology and biology of relapse after stem cell transplantation. Bone Marrow Transplant. 2018;53(11):1379–89.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schmid C, Labopin M, Nagler A, Niederwieser D, Castagna L, Tabrizi R, et al. Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood. 2012;119(6):1599–606.

Article  CAS  PubMed  Google Scholar 

de Lima M, Porter DL, Battiwalla M, Bishop MR, Giralt SA, Hardy NM, et al. Proceedings from the National Cancer Institute’s second international workshop on the biology, prevention, and treatment of relapse after hematopoietic stem cell transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation. Biol Blood Marrow Transplant. 2014;20(1):4–13.

Article  PubMed  Google Scholar 

Zeiser R, Vago L. Mechanisms of immune escape after allogeneic hematopoietic cell transplantation. Blood. 2019;133(12):1290–7.

Article  CAS  PubMed  Google Scholar 

Nowak J. Role of HLA in hematopoietic SCT. Bone Marrow Transplant. 2008;42(Suppl 2):S71–6.

Article  CAS  PubMed  Google Scholar 

Raulet DH. Missing self recognition and self tolerance of natural killer (NK) cells. Semin Immunol. 2006;18(3):145–50.

Article  CAS  PubMed  Google Scholar 

Ruggeri L, Aversa F, Martelli MF, Velardi A. Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self. Immunol Rev. 2006;214(1):202–18.

Article  CAS  PubMed  Google Scholar 

Masuda K, Hiraki A, Fujii N, Watanabe T, Tanaka M, Matsue K, et al. Loss or down-regulation of HLA class I expression at the allelic level in freshly isolated leukemic blasts. Cancer Sci. 2007;98(1):102–8.

Article  CAS  PubMed  Google Scholar 

Booman M, Douwes J, Glas AM, Riemersma SA, Jordanova ES, Kok K, et al. Mechanisms and effects of loss of human leukocyte antigen class II expression in immune-privileged site-associated B-cell lymphoma. Clin Cancer Res. 2006;12(9):2698–705.

Article  CAS  PubMed  Google Scholar 

Vago L, Perna SK, Zanussi M, Mazzi B, Barlassina C, Stanghellini MTL, et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med. 2009;361(5):478–88.

Article  CAS  PubMed  Google Scholar 

Vago L, Toffalori C, Ahci M, Lange V, Lang K, Todaro S, et al. Incidence of HLA Loss in a global multicentric cohort of post-transplantation relapses: results from the Hlaloss collaborative study. Blood. 2018;132(Supplement 1):818.

Article  Google Scholar 

Christopher MJ, Petti AA, Rettig MP, Miller CA, Chendamarai E, Duncavage EJ, et al. Immune escape of relapsed AML cells after allogeneic transplantation. N Engl J Med. 2018;379(24):2330–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Toffalori C, Zito L, Gambacorta V, Riba M, Oliveira G, Bucci G, et al. Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nat Med. 2019;25(4):603–11.

Article  CAS  PubMed  Google Scholar 

Gambacorta V, Beretta S, Ciccimarra M, Zito L, Giannetti K, Andrisani A, et al. Integrated multiomic profiling identifies the epigenetic regulator PRC2 as a therapeutic target to counteract leukemia immune escape and relapse. Cancer Discov. 2022;12(6):1449–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jones SN, Hancock AR, Vogel H, Donehower LA, Bradley A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci U S A. 1998;95(26):15608–12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 1993;7(7A):1126–32.

Article  CAS  PubMed  Google Scholar 

Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein. Cell Mol Life Sci. 1999;55(1):96–107.

Article  CAS  PubMed  Google Scholar 

Ho J, Schmidt D, Lowinus T, Ryoo J, Dopfer EP, Gonzalo Nunez N, et al. Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation. Blood. 2022;140(10):1167–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Long J, Parkin B, Ouillette P, Bixby D, Shedden K, Erba H, et al. Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. Blood. 2010;116(1):71–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weisberg E, Halilovic E, Cooke VG, Nonami A, Ren T, Sanda T, et al. Inhibition of wild-type p53-expressing AML by the novel small molecule HDM2 inhibitor CGM097. Mol Cancer Ther. 2015;14(10):2249–59.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fang DD, Tang Q, Kong Y, Rong T, Wang Q, Li N, et al. MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models. Cell Death Discov. 2021;7(1):90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pagliuca S, Gurnari C, Hercus C, Hergalant S, Hong S, Dhuyser A, et al. Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation. Nat Commun. 2023;14(1):3153.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Passweg JR, Baldomero H, Bader P, Bonini C, Duarte RF, Dufour C, et al. Use of haploidentical stem cell transplantation continues to increase: the 2015 European society for blood and marrow transplant activity survey report. Bone Marrow Transplant. 2017;52(6):811–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vago L. Clonal evolution and immune evasion in posttransplantation relapses. Hematology Am Soc Hematol Educ Program. 2019;2019(1):610–6.

Article  PubMed  PubMed Central  Google Scholar 

Barrett J, Blazar BR. Genetic trickery — escape of leukemia from immune attack. N Engl J Med. 2009;361(5):524–5.

Article  CAS  PubMed  Google Scholar 

Dubois V, Sloan-Béna F, Cesbron A, Hepkema BG, Gagne K, Gimelli S, et al. Pretransplant HLA mistyping in diagnostic samples of acute myeloid leukemia patients due to acquired uniparental disomy. Leukemia. 2012;26(9):2079–85.

Article  CAS  PubMed  Google Scholar 

Rovatti PE, Gambacorta V, Lorentino F, Ciceri F, Vago L. Mechanisms of leukemia immune evasion and their role in relapse after haploidentical hematopoietic cell transplantation. Front Immunol. 2020;11:147.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Muñiz P, Kwon M, Carbonell D, Chicano M, Bailén R, Oarbeascoa G, et al. Clinical Utility of the detection of the loss of the mismatched HLA in relapsed hematological patients after haploidentical stem cell transplantation with high-dose cyclophosphamide. Front Immunol. 2021;12:642087.

Article  PubMed  PubMed Central  Google Scholar 

Wang A, Li W, Zhao F, Zheng Z, Yang T, Wang S, et al. Clinical characteristics and outcome analysis for HLA loss patients following partially mismatched related donor transplantation using HLA chimerism for loss of heterozygosity analysis by next-generation sequencing. Cell Transplant. 2022;31:9636897221102902.

Article  PubMed  Google Scholar 

Wu H, Shi J, Luo Y, Yu J, Lai X, Liu L, et al. Assessment of patient-specific human leukocyte antigen genomic loss at relapse after antithymocyte globulin-based T-Cell-replete haploidentical hematopoietic stem cell transplant. JAMA Netw Open. 2022;5(4):e226114.

Article  PubMed  PubMed Central